Theratechnologies Inc. announced data from two poster presentations at the 24th International AIDS Conference (AIDS 2022), being held from July 29 to August 2 in Montreal, Canada and virtually. The new data provide key understandings on the potential of Trogarzo® (ibalizumab) to evolve treatment paradigms for heavily treatment-experienced HIV populations on complex regimens.
Read the full press release here.
Source : Theratechnologies Inc.
Related HIV and Co-Infections News
-
TheBodyPro: Broadly neutralizing antibodies are back in the conversation about how HIV treatment will evolve
-
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment
-
aidsmap: Switching to an integrase inhibitor can raise diabetes risk in people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.